These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15923589)

  • 21. Oxaliplatin: a welcome addition to our therapeutic armamentarium.
    Chu E
    Clin Colorectal Cancer; 2002 Aug; 2(2):72. PubMed ID: 12453318
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase III aflibercept-chemotherapy combination trial shows benefit in previously treated metastatic colorectal cancer patients.
    Oncology (Williston Park); 2011 Nov; 25(12):1213. PubMed ID: 22229217
    [No Abstract]   [Full Text] [Related]  

  • 23. Stop and go: yes or no?
    Hochster HS
    J Clin Oncol; 2009 Dec; 27(34):5677-9. PubMed ID: 19786651
    [No Abstract]   [Full Text] [Related]  

  • 24. Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-Fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group 0103.
    Comella P
    Clin Colorectal Cancer; 2003 Nov; 3(3):186-9. PubMed ID: 14706179
    [No Abstract]   [Full Text] [Related]  

  • 25. [New prospects in the treatment of advanced colorectal tumors. Barcelona, June 20-22, 2002].
    Longo F; Mansueto G
    Tumori; 2002; 88(4):A18-20. PubMed ID: 12402834
    [No Abstract]   [Full Text] [Related]  

  • 26. Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
    Booth C
    J Clin Oncol; 2008 Oct; 26(28):4693-4; author reply 4694-5. PubMed ID: 18824719
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of carcinoma of the colorectum. The contribution of oxaliplatin].
    Ravaioli A; Tassinari D; Panzini I
    Tumori; 2000; 86(3 Suppl):S37-41. PubMed ID: 10969616
    [No Abstract]   [Full Text] [Related]  

  • 28. [Oxaliplatin].
    Bascioni R
    Suppl Tumori; 2004; 3(4):S111-2. PubMed ID: 15206232
    [No Abstract]   [Full Text] [Related]  

  • 29. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
    Fisher MD
    Clin Colorectal Cancer; 2001 Aug; 1(2):85-6. PubMed ID: 12445365
    [No Abstract]   [Full Text] [Related]  

  • 31. Sequential chemotherapy for colorectal cancer.
    Seymour M
    Lancet Oncol; 2011 Oct; 12(11):987-8. PubMed ID: 21903471
    [No Abstract]   [Full Text] [Related]  

  • 32. [Cost effectiveness analysis of two adjuvant regimens in the treatment of colorectal cancer: an interpretation of the MOSAIC Study].
    Rebesco B; Cantagalli E; Amalfitano ME
    Tumori; 2005; 91(6):suppl 1-10. PubMed ID: 16457161
    [No Abstract]   [Full Text] [Related]  

  • 33. Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
    Allegra C; George T; Yothers G
    J Natl Cancer Inst; 2011 Jan; 103(1):4-5. PubMed ID: 21123834
    [No Abstract]   [Full Text] [Related]  

  • 34. Oxaliplatin (Eloxatin) for advanced colon cancer.
    Med Lett Drugs Ther; 2003 Jan; 45(1148):7-8. PubMed ID: 12571541
    [No Abstract]   [Full Text] [Related]  

  • 35. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
    Malik Z; Eng C
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
    [No Abstract]   [Full Text] [Related]  

  • 36. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.
    Chang DZ; Abbruzzese JL
    Clin Adv Hematol Oncol; 2005 May; 3(5):400-4. PubMed ID: 16167013
    [No Abstract]   [Full Text] [Related]  

  • 37. Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer.
    Del Freo A; Fiorentini G; Sanguinetti F; Muttini MP; Pennucci C; Mambrini A; Pacetti P; Della Seta R; Lombardi M; Torri T; Cantore M
    In Vivo; 2006; 20(6A):743-6. PubMed ID: 17203759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
    Longo F; Mansueto G
    Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
    [No Abstract]   [Full Text] [Related]  

  • 39. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
    Saam J; Critchfield GC; Hamilton SA; Roa BB; Wenstrup RJ; Kaldate RR
    Clin Colorectal Cancer; 2011 Sep; 10(3):203-6. PubMed ID: 21855044
    [No Abstract]   [Full Text] [Related]  

  • 40. Always look at the bright side of drugs?
    Nygren P
    Acta Oncol; 2015 Feb; 54(2):145-7. PubMed ID: 25608927
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.